This interview from Charlie Roses touches on many items and Nobel Prize Winner Muhammad Yunus adds what he has been able to accomplish in his part of the world in Bangladesh and how some of those principles can be applied here, coming together of both sides, different minds, different ideas that can...
Posted to
The Medical Quack .... by Barbara Duck
on 10-28-2008
Filed under: Medically Related, Insurance, Other Items of Interest, My Commentaries, healthcare, Biotech, Cancer, Pharmaceuticals, R and D, Economy, Banking, Milken Institute, Mahammed Yunus, Milken, Charlie Rose
It should be the discretion of individual physicians, not insurance companies or pharmacies, to substitute a branded biologic for a biosimilar, which goes back to putting the physician in the decision making process, not the non clinical analyzers. While the search for "cheap" continues...
Posted to
The Medical Quack .... by Barbara Duck
on 08-14-2008
Filed under: Medically Related, Technology, My Commentaries, DNA, Genomics, Biotech, Research, Congress, Pharmaceuticals, Biosimilars
A new possible term in the world of Biotech, Biogenerics? We currently have Pharmacogenomics working and now perhaps an interest with the Generic Drug business investing in Biotech as well or perhaps the availability of a generic without a long patent protection period? I am not quite sure...
While pharmaceutical companies are struggling , Biotech continues to grow at a rapid rate, and is part of the reason for pharma’s big investments in bio tech companies. Innovative and new products continue to flow, although there are some downsides with companies that fail to meet goals and thus...